The Filing Desk

Bioventus

BVS · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

BVS · Last close · November 13, 2026
$10.66
Value Bioventus yourself

Bioventus' revenue fell 0.9% to $568 million in fiscal 2025. Its operating margin was 9.5%, up from −2.6% a year earlier. Free cash flow was $72 million, up 90.8%. The diluted share count rose 6.8%.

BIOVENTUS INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001665988-26-000011 Updated
Revenue
$568M
0.9%
Operating margin
9.5%
12.2 pts
Net income
$23M
 
Free cash flow
$72M
90.8%
Return on capital
11.1%
13.3 pts
Market cap
$773M
Nov 13 close
P/E
13.3x
On $0.80 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Bioventus does

Bioventus is a medical device company focused on relieving pain and treating musculoskeletal problems, which affect bones, joints and muscles. Its products fall into three businesses: pain treatments, surgical solutions and restorative therapies.

Pain treatments include hyaluronic acid injections for knee osteoarthritis and a platelet-rich plasma system, as well as nerve stimulation products it is developing. Surgical solutions include ultrasonic tools that precisely cut bone in spine, brain and other surgery, and bone graft substitutes that help bones fuse after surgery. Restorative therapies include a low-intensity pulse ultrasound device for fractures that do not heal in the usual way. It says its injections, bone graft and fracture products account for most of its sales.

It has two reporting segments, U.S. and International, which made up 88% and 12% of its net sales in 2025.

Its biggest risks, as it describes them

  • It depends on a limited number of products for its revenue and profits.
  • It may be unable to develop, acquire or sell new products and expanded uses.
  • It might need extra capital to fund its operations and growth.
  • Weak financial controls could lead to errors in its reports.
  • It faces legal proceedings, including a shareholder derivative lawsuit.
From Bioventus's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments4430374251
Debt incl. finance leases358418406346304
Net debt (negative means net cash)314388369304252
Net debt to EBITDA6.7x——8.9x2.5x
Debt to equity0.8x1.3x2.3x2.3x1.6x
Interest coverage2.1x−9.3x−2.5x−0.4x2.0x
Current ratio1.4x0.9x1.5x1.3x1.7x
Quick ratio1.1x0.6x1.0x0.9x1.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Bioventus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Bioventus says to expect

  • Full year 2026: adjusted earnings per shareReaffirming its Adjusted EPS* guidance of $0.75 to $0.79 per diluted share.
  • Full year 2026: net salesUpdating Net Sales guidance to $590 million to $595 million, reflecting growth of approximately 4% to 5%.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 2, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Bioventus reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 95 of 98 of 9
Rule of 401.6%18.5%11.8%
Altman Z''−0.83−0.790.54
Accruals ratio−15.7%−9.7%−7.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassPass
F-score4 of 95 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Bioventus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BioventusFY25−0.9%9.5%12.7%11.1%2.5x8
UFP TechnologiesFY2519.5%15.3%—14.4%1.0x5Compare
AtriCureFY2514.9%−1.8%9.0%−1.9%−8.9x7Compare
TransMedics GroupFY2537.1%17.9%22.1%27.5%−0.2x7Compare
GlaukosFY2532.3%−39.3%−4.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue340321431512512573568
Revenue growth—−5.6%34.2%18.9%0.0%11.9%−0.9%
Gross profit249234303331328388388
Research and development11111924131412
Operating income312112−167−82−1554
Net income71619−159−156−3623
Diluted EPS (US$)——−0.15−2.59−2.49−0.560.33
Diluted shares (millions)——4661636469
Cash flow
Cash from operations417223−14153975
Capital expenditure217142713
Free cash flow38559−1583872
Dividends paid0000000
Share buybacks0000000
Acquisitions002630000
Stock-based compensation00201831313
Balance sheet at fiscal year end
Cash and short-term investments64874430374251
Debt incl. finance leases—188358418406346304
Total assets—4941,2261,373811728684
Total liabilities—350618960590542455
Shareholders' equity——459325174148184
Margins and ratios
Gross margin73.3%72.7%70.2%64.7%64.1%67.7%68.3%
Operating margin9.2%6.6%2.8%−32.7%−15.9%−2.6%9.5%
Net margin2.0%5.1%4.5%−31.0%−30.5%−6.3%4.0%
Free cash flow margin11.3%17.2%2.2%−2.9%1.6%6.6%12.7%
Rule of 40 (growth + FCF margin)—11.6%36.4%15.9%1.6%18.5%11.8%
Return on capital———−15.3%−9.3%−2.2%11.1%
Return on equity———−40.5%−62.6%−22.5%13.7%
Return on assets——2.2%−12.2%−14.3%−4.7%3.2%
Net debt to EBITDA—2.0x6.7x——8.9x2.5x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Bioventus' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Bioventus.